Retatrutide: Four Phase 3 Trials Complete, BLA Filing Set for Q1 2027 — What the TRIUMPH Data Mean for the Peptide Research Landscape

Key takeaways

• Eli Lilly announced positive topline results from TRIUMPH-2 and TRIUMPH-3 on 23 July 2026, completing the four-trial core TRIUMPH Phase 3 programme for retatrutide.
• TRIUMPH-2 (obesity plus type 2 diabetes, n = 1,152) recorded up to 20.8% weight loss at 80 weeks; TRIUMPH-3 (severe obesity plus established cardiovascular disease, n = 1,949) recorded up to 22.6% at 80 weeks.
• The broader programme spans weight loss of 20.8–28.7% across all four registrational trials, with the highest results in participants without diabetes.
• Lilly confirmed a Biologics Licence Application (BLA) to the FDA, planned for Q1 2027; approval is not anticipated before 2027 at the earliest, with some analysts projecting early-to-mid 2028.
• Retatrutide remains strictly investigational in both the United States and the United Kingdom; it is not approved by the FDA or EMA.

What retatrutide is and how it works

Retatrutide, developed by Eli Lilly under the code LY3437943, is a synthetic peptide that simultaneously activates three incretin and metabolic receptors: GLP-1, GIP, and glucagon. It is the first triple agonist to reach Phase 3.

The mechanistic logic underpinning its efficacy profile rests on this receptor combination. The glucagon receptor agonism is believed to be a key contributor to hepatic benefits, promoting fat oxidation in the liver — a mechanism absent from GLP-1-only or dual GIP/GLP-1 agonists such as semaglutide and tirzepatide. At a systemic level, activating all three pathways simultaneously is thought to produce additive satiety, improved insulin sensitivity, and enhanced energy expenditure.

The TRIUMPH Phase 3 programme: trial by trial

TRIUMPH-4 (December 2025): first registrational readout

Phase 3 TRIUMPH-4 reported in December 2025, with participants losing up to 28.7% of body weight (an average of 32.3 kg / 71.2 lbs) at 68 weeks — the first successful Phase 3 readout from the programme. This population comprised adults with obesity and knee osteoarthritis, without type 2 diabetes.

TRIUMPH-1 (May 2026): pivotal obesity trial

In an announcement published on 21 May 2026, Eli Lilly shared results of the TRIUMPH-1 study, which involved 2,339 participants randomised to receive retatrutide 4 mg, 9 mg, 12 mg, or placebo. At 80 weeks, participants on 4 mg lost an average of 17.6% of body weight, compared with 23.7% on 9 mg, 25.0% on 12 mg and 3.9% on placebo.

Patients with baseline BMI ≥35 who remained in the trial for 104 weeks lost 30.3% on average, with no apparent plateau observed. A nested sleep apnoea substudy, presented at the American Diabetes Association Scientific Sessions on 6 June 2026, showed a 60.6% reduction in apnoea-hypopnoea index (AHI) from a severe baseline.

TRIUMPH-2 (July 2026): obesity with type 2 diabetes

TRIUMPH-2 evaluated retatrutide in adults with type 2 diabetes and obesity or overweight. The trial was randomised, double-blind, and placebo-controlled, comparing once-weekly subcutaneous retatrutide against placebo.

TRIUMPH-2, confirmed on 23 July 2026, enrolled 1,152 patients and recorded up to 20.8% weight loss and up to 1.6 percentage points HbA1c reduction at 80 weeks. Granular glycaemic data indicate, per GLP-3 Wiki, that HbA1c reductions at 80 weeks from a baseline of 7.7% were −1.4% at 4 mg, −1.6% at 9 mg, and −1.5% at 12 mg versus −0.2% on placebo, with the largest glycaemic reduction occurring on the 9 mg arm rather than the 12 mg arm — meaning the weight-loss and glycaemic dose-response curves are not identical.

The most common adverse events were gastrointestinal and dose-related, including diarrhoea (27.4–33.6% across doses versus 13.2% on placebo), nausea (13.7–28.0% versus 8.0%), and constipation (14.0–16.8% versus 9.4%).

Weight loss and glycaemic improvement in this diabetes population were lower than in the non-diabetic TRIUMPH-1 population (28.3%) — a pattern also observed in TRANSCEND-T2D-1 (16.8%), Lilly's dedicated diabetes programme.

TRIUMPH-3 (July 2026): severe obesity with established cardiovascular disease

TRIUMPH-3 tested retatrutide in the highest-risk weight-management population studied to date: adults with severe obesity (average BMI 40.4 kg/m², average weight 111.4 kg) who already had established cardiovascular disease. Lilly reported on 23 July 2026 that the trial met its primary endpoint.

In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks. Beyond weight, cardiometabolic risk factors at 80 weeks on the 12 mg dose included a 37.0% reduction in triglycerides, a 51.2% reduction in hsCRP, a 16.5% reduction in non-HDL cholesterol, a 9.3 mmHg decrease in systolic blood pressure, and a 19.0 cm reduction in waist circumference.

Regulatory pathway and filing timeline

Lilly confirmed plans to submit a Biologics Licence Application (BLA) for retatrutide to the FDA in Q1 2027. The choice of a BLA rather than a New Drug Application (NDA) reflects retatrutide's classification as a peptide-based biologic rather than a small-molecule drug — the same pathway used for semaglutide and tirzepatide.

The filing is now expected in Q1 2027, with earlier estimates having pointed to a Q4 2026 NDA filing. Retatrutide remains investigational and is not yet approved in the UK or the United States, with regulatory submission still pending and approval not anticipated before 2027 at the earliest. Some sources suggest, based on standard FDA review timelines of twelve months following acceptance, that US patient access could realistically begin in early-to-mid 2028.

Lilly also stated that the Phase 3 programme supports planned regulatory submissions for obesity associated with knee osteoarthritis pain and obstructive sleep apnoea, potentially broadening the drug's future clinical indications.

How retatrutide compares to approved agents

Tirzepatide has generally produced greater average weight loss in obesity trials — around 21% versus approximately 15% for semaglutide — and retatrutide's data across the TRIUMPH programme exceed both.

Retatrutide has produced the highest weight loss yet reported in a Phase 3 obesity trial, above 28%. It remains investigational, with a regulatory filing expected and approval not likely before 2027 or 2028.

The cardiovascular data from TRIUMPH-3 are notable insofar as they demonstrate efficacy and cardiometabolic signal in an already high-risk population — a meaningful data point for eventual label discussions, though the ongoing TRIUMPH-CVOT trial, which has MACE as its primary endpoint, remains the trial a regulator would need to see before broad cardiovascular labelling could be granted. TRIUMPH-CVOT enrols approximately 10,000 participants with established cardiovascular disease over a three-to-four year timeline with MACE as the primary endpoint.

What this means for UK research procurement

Retatrutide has no approved status in the UK and no EMA marketing authorisation application has been announced. Procurement teams should be aware that retatrutide is still investigational; it is not FDA approved, it is not EMA approved, and all current use remains strictly research-use only.

Given the compound's peptide classification, any reference material intended for analytical purposes — for instance, for HPLC method development or mass spectrometry reference work related to GLP-1 receptor agonists — must be sourced through suppliers that can provide appropriate documentation of origin, purity, and legitimate research-use provenance. The timeline to UK availability via a licensed pharmaceutical route remains uncertain pending EMA review of any future marketing authorisation application, which Lilly has not yet publicly confirmed.

The completion of the TRIUMPH programme is, however, a significant procedural milestone: it means the full Phase 3 data package for the compound now exists, and procurement teams assessing the competitive landscape of next-generation incretin therapies have a substantially clearer picture of where retatrutide sits relative to currently approved agents.

This briefing is for research-procurement information purposes only. Retatrutide is an investigational compound and is not approved for clinical use in the United Kingdom or any other jurisdiction covered by this publication.